Skincare Mondays | Glycerin: The Unsung Hero of Skincare
DID YOU KNOW?
Glycerin is among the most popular ingredients in beauty products, behind water and fragrance.1 With a 50+ year history of use, glycerin is a deceptively simple molecule classified as a powerful humectant that is anything but basic.
Glycerin is recognized by the U.S. Food & Drug Administration (FDA) as an over-the-counter skin protectant when used between 20-45%.2
…
DID YOU KNOW?
Glycerin is among the most popular ingredients in beauty products, behind water and fragrance.1 With a 50+ year history of use, glycerin is a deceptively simple molecule classified as a powerful humectant that is anything but basic.
Glycerin is recognized by the U.S. Food & Drug Administration (FDA) as an over-the-counter skin protectant when used between 20-45%.2
… Continue reading "Skincare Mondays | Glycerin: The Unsung Hero of Skincare"
This month’s Patient Buzz includes articles that sought to predict the top skincare trends for 2023.
Are you in the know about the latest trends? Peruse this list of dermatology articles in the consumer press:
Allure: Cardi B has butt injections removed
Allure: Neuromodulator guide
Allure: Skincare trends for 2023
BestLife/Yahoo! Life: Skincare after 50
CNET: Good skin … 
As a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule.
During the SOCU Conference held in Ne … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. David E. Cohen (Charles C. and Dorothea E. Harris Professor of Dermatology, Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine) on patch testing for allergic contact dermatitis in atopic dermatitis pati … 